Eli Lilly unveils shared innovation laboratory in San Francisco
Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.
Eli Lilly has unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. Lilly Gateway Labs will offer companies direct access to Lilly scientists, team members and executives, as well as exposure to Lilly's scientific and functional expertise.
"Lilly is making this investment to help speed the discovery of medicines," said Dan Skovronsky, president of Lilly Research Laboratories and chief scientific officer, Eli Lilly and Company. "This model will enable scientists to do what they do best, in an environment that fosters scientific breakthrough. We're excited to see how it will impact our ability to deliver new solutions for patients."
Companies who work in Lilly Gateway Labs will have the opportunity to collaborate with Lilly on projects of mutual interest, participate in shared learning forums with Lilly experts and partners, and have the potential for financial investment from Lilly, venture funds, or both.
"Lilly chose the Bay Area as the location for Lilly Gateway Labs for many reasons, including the ability to tap into the hotbed of biotech innovation already based here," said Julie Gilmore, site head and chief operations officer, Lilly Gateway Labs. "We're excited to further extend our California footprint because of the supportive scientific environment which enables all aspects of drug discovery."
With over 65,000 sq. ft of space, Lilly Gateway Labs offers 32 state-of-the-art, flexibly designed private lab modules. Each module includes lab space for six to eight scientists, office space, and work stations. The space was designed with open areas for collaboration, where scientific symposia and programming will be hosted by Lilly for companies at the site as well as the broader Bay Area scientific community.
"Healthcare is the fastest growing sector of California's economy and Lilly Gateway Labs brings exciting opportunities for partnerships and innovation in drug research and development in South San Francisco that will help lead to groundbreaking therapies and improved patient care," said Rob Lapsley, President and CEO, California Business Roundtable. "California's life sciences industry is one of the nation's – and the world's – leading life sciences hubs, and we look forward to their leadership in South San Francisco to grow new companies and jobs into the future."
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance